{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T08:51:35Z","timestamp":1791103895396,"version":"4.1.0"},"publisher-location":"Chichester, UK","reference-count":42,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd004800.pub2","type":"reference-entry","created":{"date-parts":[[2005,4,22]],"date-time":"2005-04-22T10:35:41Z","timestamp":1114166141000},"source":"Crossref","is-referenced-by-count":51,"title":["Sulfasalazine for ankylosing spondylitis"],"prefix":"10.1002","author":[{"given":"Junmin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,4,20]]},"reference":[{"key":"10.1002\/14651858.CD004800.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/art.1780391209","article-title":"Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis: a Department of Veterans Affairs Cooperative Group","volume":"39","author":"Clegg","year":"1996","journal-title":"Arthritis & Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD004800.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/rheumatology\/29.1.41","article-title":"A controlled trial of sulphasalazine treatment of chronic ankylosing spondylitis: failure to demonstrate a clinical effect","volume":"29","author":"Corkill","year":"1990","journal-title":"British Journal of Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD004800.pub2-BIB3|cit3","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/rheumatology\/28.5.410","article-title":"Sulphasalazine therapy in ankylosing spondylitis: its effect on disease activity, immunoglobulin A and the complex immunoglobulin A-alpha-1-antitrypsin","volume":"28","author":"Davis","year":"1989","journal-title":"British Journal of Rheumatology"},{"issue":"6552","key":"10.1002\/14651858.CD004800.pub2-BIB4|cit4","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1136\/bmj.293.6552.911","article-title":"Sulphasalazine in ankylosing spondylitis: A double blind controlled study in 60 patients","volume":"293","author":"Dougados","year":"1986","journal-title":"British Medical Journal"},{"issue":"5","key":"10.1002\/14651858.CD004800.pub2-BIB5|cit5","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/ard.45.5.396","article-title":"Sulphasalazine in ankylosing spondylitis","volume":"45","author":"Feltelius","year":"1986","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"8","key":"10.1002\/14651858.CD004800.pub2-BIB6|cit6","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/rheumatology\/32.8.729","article-title":"The course of established ankylosing spondylitis and the effects of sulphasalazine over 3 years","volume":"32","author":"Kirwan","year":"1993","journal-title":"British Journal of Rheumatology"},{"issue":"5-6","key":"10.1002\/14651858.CD004800.pub2-BIB7|cit7","first-page":"171","article-title":"Sulphasalazine in the treatment of ankylosing spondylitis. [Serbocroatian]","volume":"112","author":"Krajnc","year":"1990","journal-title":"Lijecnicki Vjesnik"},{"issue":"9","key":"10.1002\/14651858.CD004800.pub2-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/art.1780310905","article-title":"Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial","volume":"31","author":"Nissila","year":"1988","journal-title":"Arthritis & Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD004800.pub2-BIB9|cit9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s003930200024","article-title":"Sulfasalazine in ankylosing spondylitis: a prospective, randomized, double-blind placebo-controlled study and comparison with other controlled studies. [German]","volume":"61","author":"Schmidt","year":"2002","journal-title":"Zeitschrift fur Rheumatologie"},{"issue":"8","key":"10.1002\/14651858.CD004800.pub2-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.1780390819","article-title":"Which is the active moiety of sulfasalazine in ankylosing spondylitis? A randomized, controlled study","volume":"39","author":"Taggart","year":"1996","journal-title":"Arthritis & Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD004800.pub2-BIB11|cit11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF02208032","article-title":"Sulphasalazine in ankylosing spondylitis. A radiological, clinical and laboratory assessment","volume":"10","author":"Taylor","year":"1991","journal-title":"Clinical Rheumatology"},{"issue":"Suppl","key":"10.1002\/14651858.CD004800.pub2-BIB12|cit12","first-page":"29","article-title":"Sulphasalazine treatment in ankylosing spondylitis: A comparison of sulphasalazine with placebo","volume":"30","author":"Winkler","year":"1989","journal-title":"Magyar Reumatologia"},{"issue":"3A","key":"10.1002\/14651858.CD004800.pub2-BIB13|cit13","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/eye.2000.84","article-title":"Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis","volume":"14","author":"Benitez-Del-Castillo","year":"2000","journal-title":"Eye"},{"issue":"10","key":"10.1002\/14651858.CD004800.pub2-BIB14|cit14","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1136\/ard.61.10.941","article-title":"A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies","volume":"61","author":"Burgos-Vargas","year":"2002","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"5","key":"10.1002\/14651858.CD004800.pub2-BIB15|cit15","first-page":"727","article-title":"A short-term follow-up of enthesitis and arthritis in the active phase of juvenile onset spondyloarthropathies","volume":"20","author":"Burgos-Vargas","year":"2002","journal-title":"Clinical & Experimental Rheumatology"},{"key":"10.1002\/14651858.CD004800.pub2-BIB16|cit16","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1002\/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C","article-title":"Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondyloarthropathies: a Department of Veterans Affairs Cooperative Study","volume":"42","author":"Clegg","year":"1999","journal-title":"Arthritis & Rheumatism"},{"issue":"Suppl 13","key":"10.1002\/14651858.CD004800.pub2-BIB17|cit17","first-page":"109","article-title":"A controlled, double-blind and randomized international multicenter study on sulphasalazine versus placebo in patients with spondylarthropathies","volume":"13","author":"Dekeyser","year":"1995","journal-title":"Clinical & Experimental Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD004800.pub2-BIB18|cit18","first-page":"255","article-title":"Treatment of ankylosing spondylarthritis with salazosulfapyridin. A double-blind, controlled study in 60 patients. [French]","volume":"54","author":"Dougados","year":"1987","journal-title":"Revue du Rhumatisme et des Maladies Osteo Articulaires"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004800.pub2-BIB19|cit19","first-page":"80","article-title":"Sulfasalazine in Spondylarthropathies","volume":"49","author":"Dougados","year":"1990","journal-title":"Zeitschrift fur Rheumatologie"},{"key":"10.1002\/14651858.CD004800.pub2-BIB20|cit20","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/art.1780380507","article-title":"Sulfasalazine in the treatment of spondyloarthropathy. A randomized, multicenter, double-blind, placebo-controlled study","volume":"38","author":"Dougados","year":"1995","journal-title":"Arthritis & Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD004800.pub2-BIB21|cit21","first-page":"733","article-title":"Persistence of enthesopathic changes in patients with spondylarthropathy during a 6-month follow-u","volume":"13","author":"Lehtinen","year":"1995","journal-title":"Clinical & Experimental Rheumatology"},{"issue":"11","key":"10.1002\/14651858.CD004800.pub2-BIB22|cit22","first-page":"2082","article-title":"Antibodies to Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis in ankylosing spondylitis: effect of sulfasalazine treatment","volume":"21","author":"Nissila","year":"1994","journal-title":"Journal of Rheumatology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD004800.pub2-BIB23|cit23","doi-asserted-by":"crossref","first-page":"90s","DOI":"10.1016\/0197-2456(95)90513-5","article-title":"Longitudinal analysis of binary data in the V.A. Cooperative Study of sulfasalazine for the treatment of seronegative spondyloarthropathies","volume":"16","author":"Reda","year":"1995","journal-title":"Controlled Clinical Trials"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD004800.pub2-BIB24|cit24","first-page":"69","article-title":"Sulphasalazine in ankylosing spondylitis: a prospective, randomized, double-blind, placebo-controlled study and meta-analysis of other controlled studies","volume":"59","author":"Schmidt","year":"2000","journal-title":"Zeitschrift fur Rheumatologie"},{"issue":"1","key":"10.1002\/14651858.CD004800.pub2-BIB25|cit25","first-page":"95","article-title":"Which is the active moiety of sulphasalazine in ankylosing spondylitis? [abstract]","volume":"164","author":"Taggart","year":"1995","journal-title":"Irish Journal of Medical Science"},{"key":"10.1002\/14651858.CD004800.pub2-BIB26|cit26","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/art.10148","article-title":"Guidelines for the management of rheumatoid arthritis","volume":"46","year":"2002","journal-title":"Arthritis & Rheumatism"},{"issue":"8","key":"10.1002\/14651858.CD004800.pub2-BIB27|cit27","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","article-title":"Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis","volume":"44","author":"Anderson","year":"2001","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD004800.pub2-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/ard.2003.016717","article-title":"Development and preselection of criteria for short term improvement after anti-TNF\u00a6\u00c1 treatment in ankylosing spondylitis","volume":"63","author":"Brandt","year":"2004","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD004800.pub2-BIB29|cit29","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0950-3579(98)80046-0","article-title":"Spondyloarthropathy treatment: progress in medical therapy","volume":"12","author":"Dougados","year":"1998","journal-title":"Bailliere's Clinical Rheumatology"},{"key":"10.1002\/14651858.CD004800.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"iii40","DOI":"10.1136\/ard.61.suppl_3.iii40","article-title":"Conventional treatments for ankylosing spondylitis","volume":"61(Suppl III)","author":"Dougados","year":"2002","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD004800.pub2-BIB31|cit31","first-page":"1482","article-title":"Meta-analysis of sulfasalazine in ankylosing spondylitis","volume":"17","author":"Ferraz","year":"1990","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD004800.pub2-BIB32|cit32","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2165\/00002018-199106030-00005","article-title":"Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease","volume":"6","author":"Hanauer","year":"1991","journal-title":"Drug safety : an international journal of medical toxicology and drug experience"},{"key":"10.1002\/14651858.CD004800.pub2-BIB33|cit33","doi-asserted-by":"crossref","first-page":"896","DOI":"10.7326\/0003-4819-136-12-200206180-00011","article-title":"Update on spondyloarthropathies","volume":"136","author":"Khan","year":"2002","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD004800.pub2-BIB34|cit34","first-page":"1430","article-title":"Management of rheumatoid arthritis: the historical context","volume":"28","author":"Moreland","year":"2001","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD004800.pub2-BIB35|cit35","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1053\/berh.2002.0263","article-title":"Seronegative spondyloarthritides","volume":"16","author":"Olivieri","year":"2002","journal-title":"Best Practice & Research Clinical Rheumatology"},{"key":"10.1002\/14651858.CD004800.pub2-BIB36|cit36","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/gut.51.4.536","article-title":"Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines","volume":"51","author":"Ransford","year":"2002","journal-title":"Gut"},{"key":"10.1002\/14651858.CD004800.pub2-BIB37|cit37","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1136\/ard.61.suppl_3.iii1","article-title":"New treatment strategies in ankylosing spondylitis: Proceeding of the Ankylosing Spondylitis Workshop, Berlin, Germany, 18-19 Janeary 2002","volume":"61(Suppl III)","author":"Sieper","year":"2002","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD004800.pub2-BIB38|cit38","doi-asserted-by":"crossref","first-page":"iii8","DOI":"10.1136\/ard.61.suppl_3.iii8","article-title":"Ankylosing spondylitis: an overview","volume":"61(Suppl \u00a2\u00f3)","author":"Sieper","year":"2002","journal-title":"Annal of Rheumatic Disseases"},{"key":"10.1002\/14651858.CD004800.pub2-BIB39|cit39","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/rheumatology\/XXXIV.suppl_4.7","article-title":"Sulphasalazine: mechanism of action in rheumatoid arthritis","volume":"34(Suppl. 2)","author":"Smedegard","year":"1995","journal-title":"British Journal of Rheumatology"},{"key":"10.1002\/14651858.CD004800.pub2-BIB40|cit40","volume-title":"Evidence-based Rheumatology","author":"Tugwell","year":"2004"},{"key":"10.1002\/14651858.CD004800.pub2-BIB41|cit41","first-page":"945","article-title":"Which domains should be included in a core set for endpoints in ankylosing spondylitis? Introduction to the ankylosing spondylitis module of OMERACT IV","volume":"26","author":"Heijde","year":"1999","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD004800.pub2-BIB42|cit42","doi-asserted-by":"crossref","first-page":"iii24","DOI":"10.1136\/ard.61.suppl_3.iii24","article-title":"Treatment trials in ankylosing spondylitis: current and future considerations","volume":"61(Suppl III)","author":"Heijde","year":"2002","journal-title":"Annals of the Rheumatic Diseases"}],"updated-by":[{"DOI":"10.1002\/14651858.cd004800.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,11,27]],"date-time":"2014-11-27T00:00:00Z","timestamp":1417046400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD004800.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T17:40:13Z","timestamp":1628530813000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD004800.pub2"}},"subtitle":[],"editor":[{"given":"Junmin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2005,4,20]]},"references-count":42,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004800.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD004800.pub3","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2005,4,20]]}}}